Reuters logo
BRIEF-Bristol-Myers says discontinued development of drug to treat breast and gastric cancer in Q1
2017年4月27日 / 下午3点54分 / 5 个月前

BRIEF-Bristol-Myers says discontinued development of drug to treat breast and gastric cancer in Q1

April 27 (Reuters) - Bristol-Myers Squibb Co:

* Employee workforce reductions were about 900 for quarter-ended March 31, across all regions for manufacturing, selling, research and development personnel - SEC filing

* In Q1 2017, discontinued development of FS102 which was in Phase I development for treatment of breast and gastric cancer

* Will not exercise its option to purchase F-Star Alpha which was previously consolidated by company as a variable interest entity

* IPRD charge of $75 million was included in research and development expense and attributed to noncontrolling interest in Q1 Source text - (bit.ly/2oPSPvF) Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below